Evidence map›Paper›PMID 31388824›Full record

ReviewCurrent hematologic malignancy reports2019

Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Zhuang Zuo, Shaoying Li, Jie Xu, M James You, Joseph D Khoury, C Cameron Yin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Clinical Impact ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhuang ZuoDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shaoying LiDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jie XuDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M James YouDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph D KhouryDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
C Cameron YinDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. cyin@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo review the impact of next-generation sequencing (NGS) on laboratory approach of myeloproliferative neoplasms (MPNs). RECENT

findingsNext-generation sequencing has provided valuable information on the mutational landscape of MPNs and has been used for various applications, including diagnosis, risk stratification, monitoring of residual disease or disease progression, and target therapy. Most commonly, targeted sequencing of a panel of genes that have been shown to be recurrently mutated in myeloid neoplasms is used. Although numerous studies have shown the benefit of using NGS in the routine clinical care of MPN patients, the complexity of NGS data and how these data may contribute to the clinical outcome have limited the development of a standard clinical guideline. We review recent literature and discuss how to interpret and use NGS data in the clinical care of MPN patients.

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseaseAlgorithmsAllelesClonal EvolutionGenetic TestingHigh-Throughput Nucleotide SequencingHumansLeukemia, Neutrophilic, ChronicMutationMyeloproliferative DisordersPrognosisReceptors, Colony-Stimulating FactorCSF3R protein, humanReceptors, Colony-Stimulating FactorChronic neutrophilic leukemiaEssential thrombocythemiaMyeloproliferative neoplasmsNext-generation sequencingPolycythemia veraPrimary myelofibrosis

Identifiers

PMID31388824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.